Kornimate/medical-research-clean huggingface dataset:
partnership for applied research in fracture prevention programs for the elderly

Conditions: Osteoporosis With Current Fragility Fracture

Summary: during their lifetime, approximately 50% of canadian women and 30% of canadian men will experience at least one fracture due to bone fragility (ff). evidence is growing regarding prevention programs' effectiveness to prevent falls, but prevention of fractures through fall prevention programs has enjoyed limited success. falls prevention programs and post-fracture screening programs leading to pharmacological treatment are very different strategies, with a shared ultimate goal. coordination between those who repair fractures and those who manage the patient to prevent the next fracture is critical. the overarching aim of this proposal is to generate evidence-based knowledge about the effectiveness and cost-effectiveness of an integrated ff prevention program, as well as a portrait of the barriers and facilitating factors for such programs. more specifically, the objectives are: 1) to combine existing fall prevention and post-fracture management programs in the province of quebec into integrated ff prevention programs; 2) to compare the performance of these integrated programs to control sites, using a pragmatic study design; 3) to identify barriers as well as factors that improve effectiveness across different implementation milieu; and 4) to develop and engage in active knowledge transfer activities in quebec regions where integrated ff prevention programs are neither adequately nor successfully implemented. drawing upon the literature on integrated healthcare, fall and fracture prevention, we hypothesize that an integrated ff program can reduce the risk of a subsequent fracture by at least 30% in the population of interest. the proposed team is poised to develop new interdisciplinary collaborations among healthcare practitioners and decision makers involved in the prevention of ffs. the program is built upon existing healthcare and structures and programs and in turn, will truly measure the effectiveness of an integrated ff prevention program. the results will ultimately lead to improvements in the existing knowledge base, address policy-relevant and health systems problems, and assist in the design and implementation of ffs prevention programs.


Eligibility criteria:
inclusion criteria: * 50 years of age and over * must have a primary care physician * must be able to follow simple instructions * must have sustained a fragility fracture within three months of the recruitment date. exclusion criteria: * severe kidney insufficiency (grade 4 or 5) * advanced stage of cancer * fracture to sites not commonly associated with osteoporosis such as toe, finger, hand, foot, ankle, patella, head, and cervical spine.

Keywords: fragility fracture osteoporosis fall prevention integrated program interorganizational collaboration canada controlled clinical trial evaluation
evaluation of visual function and driving health using ocusweep in patients suffering from wet age-related macular degeneration

Conditions: Macular Degeneration

Summary: the aim is to study the use of ocusweep system especially in driving health evaluation and compare the results produced by ocusweep system to those of conventional devices. the main focus is in patients suffering from wet age-related macular degeneration. the study aims to find out how frequently these patients do not meet the european union health criteria of safe driving and how ocusweep finds these patients from a population of patients being treated in a busy medical retina clinic. the tests of ocusweep system are compared against conventional visual field tests, contrast sensitivity tests, visual acuity tests and tests showing anatomical changes related to wet age-related macular degeneration (optical coherence tomography, fundus photography and fluorescein or indocyanine green angiography).


Eligibility criteria:
inclusion criteria: * macular degeneration or other diagnosed or suspected macular disease exclusion criteria: * pregnancy * mental disorder * dementia and alzheimers disease * prisoners

Keywords: wet age-related macular degeneration age-related macular degeneration ocusweep driving health visual field contrast sensitivity
pain prevalence in the trauma population

Conditions: Trauma

Summary: the incidence of pain in the post traumatic population is an area that has little to no investigation. this study seeks to determine the incidence and experience of pain in this vulnerable population at different time points - while in hospital, 4 weeks post injury, 3 months post injury.

this pilot study will be a convenience sample from trauma inpatients at the sunnybrook campus. the purpose of the study is twofold: to investigate the prevalence of chronic pain that develops in the trauma population at sunnybrook, and to see if neuropathic pain exists in this population, acute and/or chronically.

Eligibility criteria:
inclusion criteria: * over 16 years of age * ability to read / write in english * ability to complete an informed consent exclusion criteria: * history of chronic pain * unable to give informed consent * unable to read / write english

Keywords: trauma pain
tislelizumab combined with chemotherapy and thoracic radiotherapy in es-sclc

Conditions: Extensive-stage Small-cell Lung Cancer

Summary: this study is a single arm, open, multicenter phase ii study. the main purpose of this study was to evaluate preliminary efficacy and safety of tislelizumab combined with thoracic radiotherapy as first line therapy for extensive stage small cell lung cancer.


Eligibility criteria:
inclusion criteria: * patients aged between 18 to 80 years old (inclusive of 18th and 80th birthdays), male or female, at the time of signing the informed consent form; * confirmed small cell lung cancer of extensive stage by histology or cytology; * at least one measurable lesion by imaging studies (according to recist 1.1) with a long diameter of ≥10 mm as examined by spiral ct or mri; * within 3 days prior to treatment, an ecog score of 0 to 1; * no prior antitumor treatment for extensive stage disease (if the patient has previously received chemotherapy and/or radiotherapy in the limited stage of sclc, the treatment intent must have been curative, and there must be at least a 6-month treatment-free interval between the end of chemotherapy, radiotherapy, or chemoradiotherapy and the diagnosis of extensive stage sclc); * expected life span of ≥3 months; * good function of vital organs; * the subject voluntarily joins this study, signs the informed consent form, has good compliance, and cooperates with follow-up. exclusion criteria: * concurrent severe respiratory diseases: such as pulmonary fibrosis; * presence of psychiatric disorders, hematologic diseases, autoimmune diseases, and severe primary diseases of the heart, brain, liver, or kidneys; * uncontrolled active infections; * known or suspected allergies to the study medication and its excipients; * female patients who are pregnant or breastfeeding, or women of childbearing potential with a positive baseline pregnancy test; * prior use of antitumor treatment targeting the pd-(l)1 pathway.
use of machine-learning algorithms, biomarkers and measures of quality of life to personalize medical management of liver and heart transplant recipients

Conditions: Artificial Intelligence (AI); Hepatocellular Carcinoma (HCC); Heart Transplantation; Liver Transplantation; Machine Learning; Major Cardiovascular Event

Summary: this is an observational, low risk tissue based, non-pharmacological, retrospective-prospective study for adults heart and liver transplant patients, related to irccs azienda ospedaliero-universitaria di bologna (irccs aoubo). this clinical study is part of the national multicentric project dare. the project has the wide overarching aim to develop digital solutions for personalized healthcare.

this study is structured in two phases: 1) a retrospective phase that aims to develop ml-based scores that can allow to predict at patient level the risk of infections, cardiovascular diseases, new onset malignancies and chronic graft dysfunction, and describing the trajectory of this risk over time; 2) a prospective phase in which we test the association of biomarkers, qol and frailty assessments with the ml-scores applied prospectively in heart and liver transplant recipients.

Eligibility criteria:
retrospective cohort inclusion criteria receiving a heart or liver transplantation at irccs aoubo between january 2008 and december 2020. surviving at least 6 months after surgery receiving at least one outpatient clinical assessment, comprising clinical evaluation, standard laboratory tests, and graft ultrasound older than 18 years old exclusion criteria unavailability of medical records in the standard data repositories of irccs aoubo prospective cohort inclusion criteria older thant 18 years old receiving a heart or liver transplantation at least 6 months before study entry and being in active follow up at irccs aoubo obtaining informed consent exclusion criteria none
effects of yoga on bone metabolism in premenopausal women

Conditions: Bone Health; Osteoporosis

Summary: this study examined the effects of 8 months of yoga training on bone density and bone turnover markers in premenopausal women, ages 35-50 years. the style of yoga used was power yoga that involved postures with a jumping component. the investigators hypothesized that the yoga intervention would result in beneficial improvements in bone turnover markers, by increasing the bone formation marker and decreasing the bone resorption marker.


Eligibility criteria:
inclusion criteria: * participants had not been engaged in resistance training or in yoga exercise for at least 12 months prior to the study * did not have chronic back or joint problems or cardiovascular disease * not taking antihypertensive drugs or any medication that affects bone density * not taking hormonal contraception * they self-reported having regular menstrual cycles. exclusion criteria: * body weight more than 300 pounds

Keywords: yoga bone turnover markers bone strength bone mineral density
prospective cohort study of the effect of bariatric/metabolic surgery on morbid obesity patients with metabolic syndrome

Conditions: Obesity; Metabolic Syndrome

Summary: the purpose of this study is to determine the change in kidney function and blood pressure after gastric bypass versus conventional medical therapy in morbid obesity. the study mainly focus on glomerular filtration rate(gfr) with known relation to the renal function and 24 hours ambulatory blood pressure monitoring after intervention of gastric bypass or medical treatment.

metabolic syndrome is strongly associated with obesity and the patients with this syndrome are at increased risk for cardiovascular disease. obesity constitutes a strong risk factor for the development of chronic kidney disease. among diabetics, obesity is known to amplify the risk for kidney disease. bariatric surgery has yielded dramatic results including longitudinal loss of excess body weight and either complete reversal or significant improvement of several features of metabolic syndrome. in addition, many observational studies have demonstrated significant reduction in proteinuria after bariatric surgery. however, the changes in the component of cardiovascular problem among metabolic syndrome and changes in renal filtration function or progression to end stage kidney disease in morbidly obese patients after weight loss surgery have not been extensively studied. therefore, our study mainly focus on glomerular filtration rate(gfr) with known relation to the renal function and 24 hours ambulatory blood pressure monitoring after intervention of gastric bypass or medical treatment.

Eligibility criteria:
inclusion criteria: * morbid obesity (bmi\>30) patients with one of comorbidity (type 2 diabetes, dyslipidemia, or hypertension) * morbid obese patients (bmi\>35) exclusion criteria: * prior bariatric surgery * malignancy (any type) * end stage renal disease
interdisciplinary value-based cognitive behavioral treatment for people with persistent whiplash associated disorders.

Conditions: Whiplash Injuries

Summary: the goal of this clinical trial is to address the critical need for effective interventions by developing and testing an interdisciplinary values-based cognitive behavioral therapy (v-cbt) program for individuals with persistent whiplash. the main question it aims to answer are: * what is the treatment effect of the interdisciplinary values-based cognitive behavioral therapy (v-cbt) program on individuals with persistent whiplash? * what are the temporal relationships between primary and secondary outcome measures in the context of the v-cbt program? participants will undergo a replicated multiple baselines single-case experimental design (sced). twelve participants who meet specific eligibility criteria will be block-randomized to a 1, 2, or 3-week baseline phase, serving as their own controls. the intervention involves an interdisciplinary team delivering a manualized adapted v-cbt program over ten sessions, focusing on psychological and physical rehabilitation. participants will be required to attend these sessions as part of the treatment protocol. data collection includes daily online self-reports and comprehensive measurements at pre-treatment, post-treatment, and a three-month follow-up.


Eligibility criteria:
inclusion criteria: * have persistent symptoms after a whiplash injury that happened more than 3 months ago * have pain and disability defined as \> 35 % on neck disability index (ndi) * be 18 years or older * speak and read danish exclusion criteria: * denote headache as the primary problem * show red flags in the neurological and physiotherapeutic examination such as known or suspected serious spinal pathology, confirmed fracture or dislocation in the neck at the time of injury or signs of nerve root compromise (weakness, reflex changes or sensory loss) * have had spinal surgery within the past 12 months * are socially and occupationally unresolved * have daily significant functional limitations related to other pain conditions * have severe psychiatric illness * are pregnant * are not willing or able to respond to items on a daily basis.
a study to evaluate the safety, tolerability, and activity of lonafarnib and docetaxel (study p04467am1)(terminated)

Conditions: Prostate Cancer; Breast Cancer; Ovarian Cancer; Lung Cancer; Gastric Cancer

Summary: this study will determine the best doses of docetaxel and lonafarnib when the two anti-cancer agents are used in combination. patients with tumors for which treatment with docetaxel would be appropriate are eligible. a second part of the study will further examine the effectiveness of the combination treatment in men with prostate cancer.


Eligibility criteria:
inclusion criteria: * for part 1: subjects may be male or female and must be at least 18 years of age. * for part 1: cancer for which docetaxel treatment is appropriate. * for part 1: docetaxel-naïve * for part 2: subjects must be male and at least 18 years of age. * for part 2: subjects must have adenocarcinoma of the prostate confirmed by histologic/cytologic biopsy. * for part 2: subjects must have progressive, metastatic, aipc and a psa of 10 ng/ml or more after hormonal therapy prior to docetaxel treatment. progressive disease is defined as a consistently increasing serum psa level within 28 days prior to docetaxel administration. * adequate organ function within 3 weeks prior to first study drug administration. * performance status (ecog) is less than or equal to 2. * subject understands and agrees to procedures and participation by signing informed consent form. * agrees to use medically accepted form of contraception. exclusion criteria: * receipt of or need to continue to receive prohibited medications (listed in the protocol) more recently than the washout period (indicated in the protocol). * surgery within 3 weeks prior to first study drug administration. * history within 5 years prior to first study drug administration of another malignancy except adequately treated stage i/ii basal/squamous cell skin cancer. * radiation therapy to more than 25% of his/her total bone marrow during life. * radiation therapy within 3 weeks prior to first study drug administration. * known hypersensitivity to prednisone, docetaxel, polysorbate 80, lonafarnib, or any excipients associated with these medications. * known contraindication to steroid use. * known leptomeningeal or cns metastasis. * heart, vascular, or seizure disorder (detailed list in the protocol) within 6 months prior to first study drug administration. * baseline qtc interval greater than 450 msec. * grade 2 or more peripheral neuropathy or drug-related toxicity per ctcae. exceptions are noted in the protocol. * any clinically significant condition or situation that the investigator thinks would interfere with the study evaluations or subject's participation. * subject is part of staff personnel involved in the study. * subject has known clinically significant immunosuppression.
role of delay and antibiotics on perforation rate while waiting appendectomy

Conditions: Appendicitis

Summary: this study evaluates the effects of preoperative delay and antibiotics on perforation rate of appendix while waiting surgery for acute appendicitis. patients with diagnosed acute appendicitis are randomized into two urgency groups: surgery within 8 hours or surgery within 24 hours. in addition, patients are randomized to either receive antibiotics while waiting or waiting without antibiotics.


Eligibility criteria:
inclusion criteria: * acute appendicitis where surgery is planned. diagnosis of appendicitis should be verified either by clinical diagnosis with adult appendicitis score \>=16 or by diagnostic imaging (ct-scan, mri or ultrasound) showing appendicitis. all patients with symptoms at least 3 days should undergo diagnostic imaging before inclusion. exclusion criteria: * complicated appendicitis according to diagnostic imaging. the following findings indicate complicated appendicitis: extraluminal air or extraluminal fecalith; fluid collection, abscess or phlegmon next to appendix; non-enhancement appendiceal wall on contrast enhanced ct-scan. * plasma c-reactive protein \>=100 * fever measured on emergency department over 38.5 degrees celcius. * clinical generalized peritonitis or other reason that indicate immediate surgery * pregnancy, pregnancy test is taken from all fertile aged women before randomization * allergy to study antibiotics, or anaphylactic reaction after betalactam antibiotic or other contraindication for metronidazole or ongoing antibiotic treatment or patient is carrier of resistant bacteria. (this exclusion criteria are applicable only on randomization into antibiotic treatment arms) * missing written informed consent
polycystic ovary syndrome and liraglutide as add-on therapy on metformin

Conditions: PCOS; Obesity

Summary: the purpose of this study was to determine whether combined treatment with liraglutide and metformin is more effective than liraglutide or metformin as monotherapy in the treatment of obese women with polycystic ovary syndrome (pcos) who had been previously poor responders regarding weight reduction on metformin monotherapy. we anticipated greater changes in body weight in patients on combined treatment than in those on monotherapy with liraglutide or metformin.


Eligibility criteria:
inclusion criteria: * 18 years old to menopause * polycystic ovary syndrome (nichd criteria) * bmi of 30 kg/m² or higher * poor response to previous treatment with metformin for at least 3 months exclusion criteria: * type 1 or type 2 diabetes mellitus * history of carcinoma * cushing's syndrome or congenital (non-classic) adrenal hyperplasia * personal or family history of men 2 * significant cardiovascular, kidney or hepatic disease * the use of medications known or suspected to affect reproductive or metabolic functions * the use of statins, within 90 days prior to study entry

Keywords: pcos obesity glp-1 receptor agonist liraglutide metformin
p300 in early cognitive impairment in hepatitis c virus

Conditions: Hepatitis C; Cognitive Impairment

Summary: approximately 50% of patients with hepatitis c have complaints of fatigue and cognitive deficits even before the development of significant hepatic impairment.

assessing the influence of hcv infection on the development of cognitive changes involves many challenges. the frequent presence of confounding factors such as illicit drug use, depression, and cirrhosis has the potential to produce cognitive impairment and therefore obscuring the role of hcv infection as a major actor in the development of cognitive impairment. the presence of brain dysfunction in patients with liver cirrhosis is well known. zeegen et al. described in 1970, through the use of neuropsychological tests, the occurrence of cognitive changes involving mainly psychomotor speed, attention, and executive function in cirrhotics who did not have clinical criteria for hepatic encephalopathy. this condition is currently called minimal hepatic encephalopathy.

Eligibility criteria:
inclusion criteria: * newly diagnosed hcv infection exclusion criteria: * any neuropsychiatric disease that cause impaired cognition

Keywords: hepatitis c, cognitive impairment
the turkish version of the medial tibial stress syndrome score

Conditions: Medial Tibial Stress Syndrome

Summary: the medial tibial stress syndrome (mtss) score was originally developed in dutch to assess severity of disease relative to patient-reported outcome, particularly patients with mtss. the purpose of this study was to translate and cross-culturally adapt the mtss score into turkish and investigate its psychometric properties.

the medial tibial stress syndrome (mtss) score was originally developed in dutch to assess severity of disease relative to patient-reported outcome, particularly people with mtss. the purpose of this study was to translate and cross-culturally adapt the mtss score into turkish and investigate its psychometric properties. fourty-eight individuals with mtss will include. within a 7-day period after the first assessment, the participants completed the turkish version of the mtss score to evaluate test-retest reliability. cronbach's alpha (α) was used to assess internal consistency. construct validity was examined total score of pcs domain of sf-36-tr with mtss-tr total score in the first visit. concurrent validity was examined by evaluating the relationship between pain level and detmer's classification with mtss score in the first visit. the pain level of the patient assessed with visual analog scale (vas) score.

Eligibility criteria:
inclusion criteria: * patients diagnosed with mtss by a sports medicine physician * patients aged between 18 and 75 years * patients whose native language is turkish * patients who volunteered to participate in the study exclusion criteria: * having tibia fracture history, * patients with suspected stress fracture or chronic compartment syndrome, * pregnant and breastfeeding women